Clinical Trial: Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With <

Brief Summary: The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.

Detailed Summary:
Sponsor: NGM Biopharmaceuticals, Inc

Current Primary Outcome: The mean and percent change in ALP from Baseline to Week 12 [ Time Frame: 12 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: The mean and percent change in ALT from Baseline to Week 12 [ Time Frame: 12 weeks ]

Original Secondary Outcome: Same as current

Information By: NGM Biopharmaceuticals, Inc

Dates:
Date Received: February 29, 2016
Date Started: February 2016
Date Completion: June 2017
Last Updated: March 7, 2017
Last Verified: March 2017